316 related articles for article (PubMed ID: 20579582)
1. Clinical outcomes and medical care costs among medicare beneficiaries receiving therapy for peripheral arterial disease.
Jaff MR; Cahill KE; Yu AP; Birnbaum HG; Engelhart LM
Ann Vasc Surg; 2010 Jul; 24(5):577-87. PubMed ID: 20579582
[TBL] [Abstract][Full Text] [Related]
2. National health care costs of peripheral arterial disease in the Medicare population.
Hirsch AT; Hartman L; Town RJ; Virnig BA
Vasc Med; 2008 Aug; 13(3):209-15. PubMed ID: 18687757
[TBL] [Abstract][Full Text] [Related]
3. In-hospital outcomes and cost comparison of femoropopliteal reopening strategies.
Safley DM; Lindsey JB; Robertus K; House JA; Mahoney E; Allen KB; Cohen DJ
Cardiovasc Revasc Med; 2011; 12(5):292-8. PubMed ID: 21273148
[TBL] [Abstract][Full Text] [Related]
4. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program.
Ryan J; Linde-Zwirble W; Engelhart L; Cooper L; Cohen DJ
Circulation; 2009 Feb; 119(7):952-61. PubMed ID: 19204307
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
[TBL] [Abstract][Full Text] [Related]
6. Endovascular treatment of peripheral vascular disease.
Allaqaband S; Kirvaitis R; Jan F; Bajwa T
Curr Probl Cardiol; 2009 Sep; 34(9):359-476. PubMed ID: 19664498
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany.
Pietzsch JB; Geisler BP; Garner AM; Zeller T; Jaff MR
Catheter Cardiovasc Interv; 2014 Oct; 84(4):546-54. PubMed ID: 24782424
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data.
Clark MA; Bakhai A; Lacey MJ; Pelletier EM; Cohen DJ
Circulation; 2004 Jul; 110(3):259-64. PubMed ID: 15226211
[TBL] [Abstract][Full Text] [Related]
10. In-hospital costs of self-expanding nitinol stent implantation versus balloon angioplasty in the femoropopliteal artery (the VascuCoil Trial).
Greenberg D; Rosenfield K; Garcia LA; Berezin RH; Lavelle T; Fogleman S; Cohen DJ
J Vasc Interv Radiol; 2004 Oct; 15(10):1065-9. PubMed ID: 15466792
[TBL] [Abstract][Full Text] [Related]
11. Endovascular intervention for treatment of claudication: is it cost-effective?
O'Brien-Irr MS; Harris LM; Dosluoglu HH; Dryjski ML
Ann Vasc Surg; 2010 Aug; 24(6):833-40. PubMed ID: 20638623
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of mesenteric artery stenting versus surgical revascularization in chronic mesenteric ischemia.
Kougias P; Huynh TT; Lin PH
Int Angiol; 2009 Apr; 28(2):132-7. PubMed ID: 19367243
[TBL] [Abstract][Full Text] [Related]
13. The costs of drug-eluting coronary stents among Medicare beneficiaries.
Groeneveld PW; Matta MA; Greenhut AP; Yang F
Am Heart J; 2008 Jun; 155(6):1097-105. PubMed ID: 18513525
[TBL] [Abstract][Full Text] [Related]
14. Lower extremity angioplasty: impact of practitioner specialty and volume on practice patterns and healthcare resource utilization.
Vogel TR; Dombrovskiy VY; Carson JL; Haser PB; Graham AM
J Vasc Surg; 2009 Dec; 50(6):1320-4; discussion 1324-5. PubMed ID: 19837538
[TBL] [Abstract][Full Text] [Related]
15. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
[TBL] [Abstract][Full Text] [Related]
16. Design of the multicenter standardized supervised exercise training intervention for the claudication: exercise vs endoluminal revascularization (CLEVER) study.
Bronas UG; Hirsch AT; Murphy T; Badenhop D; Collins TC; Ehrman JK; Ershow AG; Lewis B; Treat-Jacobson DJ; Walsh ME; Oldenburg N; Regensteiner JG;
Vasc Med; 2009 Nov; 14(4):313-21. PubMed ID: 19808716
[TBL] [Abstract][Full Text] [Related]
17. The estimated costs and savings of medical nutrition therapy: the Medicare population.
Sheils JF; Rubin R; Stapleton DC
J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
[TBL] [Abstract][Full Text] [Related]
18. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
19. Cost determinants of percutaneous and surgical interventions for treatment of intermittent claudication from the perspective of the hospital.
Janne d'Othée B; Morris MF; Powell RJ; Bettmann MA
Cardiovasc Intervent Radiol; 2008; 31(1):56-65. PubMed ID: 17973158
[TBL] [Abstract][Full Text] [Related]
20. Lower extremity endovascular interventions: can we improve cost-efficiency?
O'Brien-Irr MS; Harris LM; Dosluoglu HH; Dayton M; Dryjski ML
J Vasc Surg; 2008 May; 47(5):982-7; discussion 987. PubMed ID: 18296016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
